Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Ototopical Antibiotics 

  • Author: Kathleen R Billings, MD; Chief Editor: Arlen D Meyers, MD, MBA  more...
 
Updated: Dec 30, 2014
 

Ototopical Advantages

In treating ear infections with antibiotics, topical delivery has a number of advantages over systemic delivery. These advantages include the following:

  • A vastly higher concentration of antibiotic can be delivered to the site of infection.
  • Medications delivered topically have no systemic effects.
  • Topical delivery allows alteration of the local microenvironment.
  • Ototopical medications are usually less expensive than comparable systemic medications.

A 0.3% antibiotic solution contains 3000 mcg/mL of antibiotic. For comparison, consider the following commonly accepted middle ear concentrations after oral administration of antibiotics.

  • Amoxicillin at 90 mg/kg (6-10 mcg/mL)
  • Cefuroxime at 500-mg dose (2-4 mcg/mL)
  • Cefpodoxime at 200-mg dose (1-2 mcg/mL)
  • Clarithromycin at 500-mg dose (2-5 mcg/mL)

Even parenteral ceftriaxone, which can deliver an exceptionally high middle ear fluid level (35 mcg/mL), cannot begin to compete with the concentration of antibiotic delivered into the middle ear by topical delivery.

These high concentrations are pharmacodynamically important for antibiotics known to have a concentration-dependent mechanism of action. Aminoglycosides and quinolones are both concentration-dependent drugs. Consequently, bacteriocidal activity and lethality of bacteriocidal kill is progressively enhanced by the extent to which the delivered concentration exceeds the minimal inhibitory concentration (MIC). Although the MIC of ciprofloxacin for Pseudomonas is reported to be as high as 256 mcg/mL, this level is not the norm. End-point MICs rarely exceed 64 mcg/mL, even for highly resistant Pseudomonas.

Consequently, the concentration of delivered antibiotic, when topical administration is used, is always well above the MIC of the relevant organism. This makes the emergence of bacterial resistance extremely improbable. The possibility for the emergence of resistance seems to be vastly lower when topical routes of administration are used as compared with drugs that are administered systemically.

An important consequence of the high concentration of antibiotics delivered when topical preparations are used is the recognition that MICs reported by clinical laboratories become irrelevant. The clinical laboratory determination of resistance is based entirely on the drug level that can be achieved by systemic administration. A Pseudomonas organism with an MIC of 8 mcg/mL for ciprofloxacin is considered resistant. Clearly, however, the same organisms are rapidly killed by 0.3% topical solution containing 3000 mcg/mL.

Characteristic of topical delivery systems is the absence of systemic effects, which is an advantage if no systemic effect is required. Systemic toxicity requires systemic exposure. Consequently, systemic reaction to topical antibiotics is extremely uncommon. Because no appreciable systemic delivery of topically administered agents occurs, the normal flora in the respiratory and gastrointestinal tracts is not exposed to antibiotics. Topical administration, therefore, avoids selecting for resistant organisms in the upper aerodigestive tract, a common mechanism by which resistant organisms develop and propagate. The absence of systemic delivery is another reason that resistance to topical administration occurs with less frequency than resistance to systemically administered agents.

The use of topical agents allows for the simultaneous modification of the local microenvironment. The pH of the external auditory canal, for example, is normally slightly acidic. The administration of an antibiotic in an acidic drop helps restore and fortify this normal host defense mechanism.

Ototopical medications are generally less expensive than systemic medications. Although the newer quinolone antibiotic drops are more expensive than some systemic antibiotics, such as amoxicillin, the quinolone drops are much less expensive than systemic quinolones. To compare the cost of amoxicillin, trimethoprim-sulfamethoxazole, or erythromycin with these ototopical preparations is not appropriate. These systemic antibiotics have a poor spectrum of activity against otic pathogens.

Next

Ototopical Disadvantages

A number of disadvantages are associated with ototopical administration of antibiotics. These disadvantages include the following:

  • Effective delivery to the infected site may be difficult or impossible.
  • Drugs administered ototopically are capable of local toxicity within the middle ear and inner ear.
  • Ototopical agents can produce local sensitivity reactions.
  • Agents administered ototopically have no systemic effect.
  • These agents can alter the microenvironment in an inappropriate way.

If the antibiotic cannot reach the infected area, the agent cannot be effective. Delivery can be impaired in a number of different ways, including the following:

  • Administration can be poor; drops aimed at the external auditory canal can fail to enter the canal.
  • The external auditory canal may be occluded with cerumen, desquamated epithelium, or mucopurulent exudate. Acute otitis media (see the images below) can result in profuse otorrhea that rapidly fills the external auditory canal with mucopurulent fluid. A column of mucopurulent fluid within the lumen of the tube or external auditory canal can prevent passage of ototopical preparations into the middle ear space.
    Healthy tympanic membrane. Healthy tympanic membrane.
    Tympanic membrane of a person with 12 hours of ear Tympanic membrane of a person with 12 hours of ear pain, slight tympanic membrane bulge, and slight meniscus of purulent effusion at bottom of tympanic membrane. Reproduced with permission from Isaacson G: The natural history of a treated episode of acute otitis media. Pediatrics. 1996; 98(5): 968-7.
  • A plugged or nonfunctioning tympanostomy tube can prevent passage of topical medications into the middle ear. Inspissated mucus or cerumen can plug a tympanostomy tube or small perforation. Exuberant granulations commonly obstruct both tympanostomy tubes and perforations.

The ear is a multifaceted organ that connects the central nervous system to the external head and neck. This structure as a whole can be thought of as 3 separate organs including the external ear, the middle ear (tympanic) (malleus, incus, and stapes), and the inner ear (labyrinth) (semicircular canals, vestibule, cochlea). The image below depicts the anatomy of the ear. For more information about the relevant anatomy, see Ear Anatomy.

Anatomy of the ear. 1 - skull, 2 - ear canal, 3 - Anatomy of the ear. 1 - skull, 2 - ear canal, 3 - pinna, 4 - tympanum, 5 - fenestra ovalis, 6 - malleus, 7 - incus, 8 - stapes, 9 - labyrinth, 10 - cochlea, 11 - auditory nerve, 12 - eustachian tube. Image courtesy of Wikimedia Commons.

Most failures of ototopical therapy are failures of delivery. Many of these problems are manageable. Swollen tissues in the external auditory canal are overcome by meticulous cleansing and placing of an otowick. The lumens of tympanostomy tubes can be cleared in the clinic using the microscope and microinstrumentation. Profuse otorrhea can be cleared from the external auditory canal long enough to apply drops using irrigation. An irrigation solution that is 50% sterile water and 50% hydrogen peroxide frequently eliminates enough material from the external auditory canal to allow passage of the medication if the agent is delivered within a few minutes after the irrigation is complete.

When at home, the ear can be flushed with a half-strength vinegar solution or acetic acid drops to facilitate placement of antibiotic drops. Managing granulation tissue is more difficult. Mechanical debridement, the use of silver nitrate, and steroid preparations often eliminate granulation tissue and permit effective entry of topical medications into the middle ear.

Toxicity from topical preparations can involve both middle ear and inner ear structures. Middle ear toxicity takes the form of irritation of the middle ear mucosa accompanied by mucosal edema and metaplasia, if the inflammatory event is frequently repeated. Propylene glycol, a common vehicle in topical preparations, is fairly irritating to middle ear mucous membranes. Ototopical preparations vary in their ability to inflame middle ear mucosa. Hydrocortisone has a mildly irritating effect. Vasocidin, an ophthalmic drop used off-label as an otic preparation, has an intense inflammatory effect on middle ear mucous membranes.

Inner ear toxicity can take 2 forms, cochlear and vestibular. Neomycin, polymyxin, and chloramphenicol are intensely ototoxic if these agents enter the inner ear. A single small dose of these preparations into the middle ear of chinchillas produces near-total cochlear hair cell loss. The effect is clearly muted in humans, or anacusis would be widespread following the use of neomycin-containing otic preparations.

A number of reasons may explain why cochlear ototoxicity is less likely in humans than in experimental animals. The round window membrane of experimental animals is considerably thinner than that of adult humans. The round window membrane of experimental animals is exposed, while this structure is relatively protected in humans. In humans, the round window membrane is frequently covered with a mucous membrane that does not permit direct contact between medications placed into the ear and the round window membrane. Aminoglycoside antibiotic molecules have a negative charge, as does the round window membrane of humans; therefore, the charges discourage movement of the antibiotic across the round window membrane. Ototopical medications are generally administered when the mucous membrane is inflamed, edematous, thickened, and often hyperplastic.

Many otolaryngologists are convinced that they have detected genuine cases of hearing loss due to aminoglycoside ototoxicity. The relative infrequency with which hearing loss occurs as a consequence of the installation of aminoglycoside drops is a tolerable risk when such preparations are clearly the most effective therapy for middle ear diseases. However, because quinoline drops lacking in ototoxic potential are currently available, the risk of aminoglycoside-induced ototoxicity is more difficult to justify.

Most reports on ototoxicity focus principally on hearing loss. In a 1998 report, Marais and Rutka emphasize that for many aminoglycoside antibiotics, vestibular toxicity is much more likely than cochlear toxicity.[1] Consequently, they have searched for vestibular manifestations of aminoglycoside ototoxicity and, unfortunately, have good evidence that clinical vestibular toxicity occurs with meaningful frequency. Rutka recently produced complete labyrinthine ablation using a commercially available ophthalmic gentamicin drop instilled twice a day through a patent tympanostomy tube.

The first case of cutaneous sensitization to neomycin was reported to have occurred in the external auditory canal as a consequence of treatment for external otitis. Since that time, the incidence of topical sensitization to neomycin appears to have increased. In the 1970s, topical sensitization was detectable in about 8% of individuals with chronic external otitis. In the 1980s, this incidence doubled to 16%, and in the 1990s, the incidence doubled again to 30-35%. The incidence of cutaneous sensitization has apparently doubled each decade for the last 3 decades, presumably as a result of widespread exposure to neomycin-containing drops.

The aminoglycosides are capable of cross-sensitization. Tobramycin sensitivity has been detected in the Netherlands, a country in which tobramycin-containing topical preparations are not approved for use. Florid sensitivity reactions are relatively easy to diagnose but are not terribly common. Low-grade sensitivity reactions, however, are much more difficult to diagnose. The approved labeling for polymyxin, neomycin, and hydrocortisone solutions warns that sensitivity reactions may be low grade and may simply manifest as drainage that does not cease. The practical consequence is that distinguishing between resistant infection and low-grade sensitivity reaction may be impossible. How many treatment failures of acute external otitis are the consequence of sensitivity reactions is unknown. Clearly, however, topical sensitization plays a significant role in chronic external otitis media.

The absence of systemic effect transforms from an advantage to a disadvantage when a systemic effect is needed. If cellulitic changes occur outside the confines of the external auditory canal, including soft tissues of the cheek, auricle, or postauricular tissues, systemic antibiotics are required.

Sometimes otorrhea in a child can be a manifestation of a diffuse upper respiratory infection with systemic manifestations. Children who have systemic signs and symptoms associated with otorrhea or who have an accompanying sinusitis or pharyngitis should not be treated with topical therapy alone. Withholding systemic antibiotics in such circumstances risks the development of either local complications from sinusitis or systemic complications, such as pneumonia, septicemia, or meningitis.

The possibility of altering the microenvironment in a counterproductive way exists if the wrong solution or preparation is used as a vehicle for topical antibiotics. One might argue that the intense middle ear inflammation produced by sulfacetamide and prednisolone (Vasocidin) is a good example of such inappropriate use. An alkaline antibiotic delivery system for external otitis creates a more hospitable environment for Pseudomonas and is thus counterproductive.

Previous
Next

Types Of Delivery

Antibiotics can be characterized in various ways. One method is to characterize antibiotics on the basis of delivery. Three types of delivery systems are available: powders, creams or ointments, and drops.

Powders have been used for many years, and various different powders are compounded on a local or regional basis. The Food and Drug Administration (FDA) has not approved any powders, and the FDA is unlikely to ever approve powders. The potential market for such preparations is much too small to justify the expense associated with the FDA approval process.

Powders have the advantage of adhering to moist surfaces and have long dwelling times within the external auditory canal, middle ear, or mastoid cavities. In a healthy mastoid cavity, powders can persist for months. In a profusely draining ear, the dwelling time is much shorter but is likely to exceed that of liquids. Powders appear to adhere tenaciously to granulation tissue, making them especially attractive for chronic suppurative otitis media. The powders are relatively easy to apply. A Sheehy-House powder insufflator is readily available and inexpensive ($10-15).

A large variety of different components have been used in powders. Most preparations are a mixture of antibacterial antibiotics, antifungal agents, and steroids. Two preparations are used at the University of Texas (UT) Southwestern Medical Center. Gold dust is composed of chloramphenicol, sulfanilamide, and hydrocortisone. Mastoid powder is comprised of ciprofloxacin powder, clotrimazole powder, dexamethasone powder, and boric acid. The mastoid powder appears more effective and is easier to apply than gold dust. Mastoid powder has a reduced tendency to clump, is much easier to disperse by blowing, and seems to distribute as a finer powder than gold dust.

Creams are used only in the treatment of diseases of the external auditory canal. Aminoglycoside ointments, such as Neosporin and/or tobramycin, can be used as single-dose therapies for external otitis. Mycelex cream is frequently chosen to treat suspected Candida infections of the external auditory canal and conchal bowl. A single application can be an effective treatment for candidiasis of the external auditory canal. At UT Southwestern, mupirocin ointment is used perioperatively to fill the external auditory canal after surgical procedures. Preference is given to this ointment because no ototoxicpotential exists.

The most commonly used ototopical preparations are drops. Drops are available in 2 forms, as single agents or as combination products. Single agent antibiotic drops are usually available as solutions. They often have very low viscosities, approaching that of water. Combination products tend to be more viscous because they are dispensed as suspensions. The physicochemical properties of steroids are such that steroids do not go readily into solution and, consequently, must be emulsified. Microemulsions have fairly low viscosities and have the clarity of solutions (eg, tobramycin and dexamethasone [TobraDex]).

A large variety of ototopical drops are available and can be separated according to the following 4 basic characteristics: presence/absence of antibiotic and type of antibiotic present, pH, viscosity, and single agents or combination products.

Previous
Next

Antibiotic Component Drops

Some ototopical preparations do not contain antibiotics. These agents rely on pH or other physical chemical properties of the solution to kill bacteria or control bacterial growth. VoSol is an acidic solution that is quite viscous, with a pH of approximately 3. This solution can be obtained with or without hydrocortisone. Domeboro solution is a modified Burow solution acidified with 2% acetic acid. Although the pH is 5, this solution is more bacteriostatic than solutions of lower pH. Consequently, some of its bacteriocidal effect must rely on the aluminum acetate component of the mixture.

Antiseptics are often used in ototopical preparations. The antiseptic can be dropped into the external auditory canal or painted on using small cotton swabs. Antiseptics are useful because of potential antibacterial and antifungal effects. Antiseptics are less likely to select for resistant organisms. Gentian violet (an aniline dye), mercurochrome (a mercury-containing compound), and cresylate (a substituted phenol) are used as topical otologic antiseptic agents. Of these agents, cresylate appears to have the most potent antibacterial and antimycotic effect.

Chloramphenicol drops have been marketed in the past, and sulfanilamide-based drops are available for ophthalmic use. Ophthalmic preparations containing sulfanilamide are occasionally indicated for otic use. Ophthalmic drops have a neutral pH and, consequently, can generally be used in the ear if deemed appropriate. Polymyxin, a cationic detergent, is commonly used in combination preparations and remains an effective antibiotic against gram-negative organisms. However, similar to neomycin, polymyxin is potentially ototoxic.

Aminoglycosides have been the mainstay of ototopical bacterial antibiotics. The oldest of these agents is neomycin, which has been available for over 40 years. Neomycin remains reasonably effective against gram-positive organisms, but its effectiveness against gram-negative organisms has declined in recent years. Pseudomonas, the most common bacterial pathogen in chronic otorrhea, has developed substantial resistance to neomycin.

In Dohar's 1996 publication, fewer than 20% of the Pseudomonas organisms recovered from infected ears retained sensitivity to neomycin.[2] Neomycin is a potent cochleotoxic agent and is highly sensitizing. Gentamicin and tobramycin are used as ototopical preparations, despite never receiving FDA approval for otic use. Tobramycin is used more widely in the United States, while gentamicin is used more commonly in Canada and Europe. Both aminoglycosides are highly effective against relevant bacteria, with tobramycin being slightly more effective against Pseudomonas in the United States. Both drugs have ototoxic potential. In their 1998 report, Marais and Rutka showed compelling evidence for vestibulotoxic effects from gentamicin otic drops.[1]

The most recently introduced topical antibacterial agents are the quinolones. These agents have an excellent spectrum of activity against relevant pathogens and lack any capacity for ototoxicity. From a strictly theoretical point of view, the quinolones are the antimicrobial agents of choice for antibacterial otic drops. Because they lack the potential for ototoxicity, quinolones are preferred to aminoglycosides for any application within the middle ear space. The American Academy of Otolaryngology - Head and Neck Surgery endorses this recommendation.

No FDA-approved ototopical agents are specifically designed to treat otomycosis. Many agents with antifungal properties are suggested in the treatment of otomycosis, but consensus is lacking regarding the best agent for this condition. Nystatin, a polyene macrolide antibiotic, is available as a cream, ointment, or powder and has a wide spectrum of activity against mycotic organisms. Miconazole cream can be applied to the ear, although clotrimazole is the most widely used topical azole. Its antibacterial effect is advantageous in treating mixed bacterial-fungal infections, but the carrier vehicle for this agent in liquid form can irritate the surrounding skin and mucosa, affecting compliance. Tolnaftate, a popular antifungal agent, can be instilled into the ear, inhibiting growth of susceptible fungi. In studies using guinea pigs, this agent did not exhibit ototoxic effects, althoughnystatinleftapersistentresidueintheround window niche.

Samarei conducted a study to determine whether there was a difference in ototoxicity between use of local ciprofloxacin and systemic ciprofloxacin in the treatment of chronic media otitis. The study cohort consisted of 72 patients, 40 of whom were treated with ciprofloxacin drops, and 32 of whom were treated with ciprofloxacin tablets. With regard to hearing threshold, there was significant difference in the 2 groups only at a frequency of 4000 Hz, at which frequency the patients receiving drops experienced improvement in hearing threshold. Samarei concluded that topical ciprofloxacin is a safe and uncomplicated ototoxic drug that is effective in the treatment of refractory chronic otitis and that it doesnot have harmful effects on hearing hairy cells when used in the usual doses.[3]

The US Food and Drug Administration (FDA) has approved the fluoroquinolone antimicrobial, finafloxacin otic suspension (Xtoro, Alcon Labs), to treat acute otitis externa caused by Pseudomonas aeruginosa and Staphylococcus aureus. The safety and efficacy of finafloxacin otic suspension were demonstrated in two clinical trials involving 1234 participants between the ages of 6 months and 85 years. Among 560 participants whose acute otitis externa was confirmed to be caused by Pseudomonas aeruginosa or Staphylococcus aureus, 70% who received Xtoro achieved clinical cure, defined as complete resolution of ear tenderness, redness, and swelling compared with 37% who received the vehicle. Finafloxacin otic suspension was also superior to the vehicle for clearing the bacteria based on ear culture and eased ear pain sooner than the vehicle. The most common adverse effects reported with finafloxacin ear drops were pruritus and nausea.[4]

Previous
Next

Other Components

The pH is an important element of antibiotic drops. As mentioned above, some preparations rely on low pH for their antibacterial and antimycotic activity. Although this works well within the external auditory canal, a low pH can be extremely painful when applied to the middle ear space. Drops of low pH can produce severe discomfort when they pass through a perforation or tympanostomy tube. Drops with a pH varying between 5 and 6 are generally tolerated well, even if they reach the middle ear space. The drops at least have a theoretical advantage of restoring the external auditory canal to normal and have some advantage in the treatment of external otitis. No evidence is available to support the fact that low pH enhances the activity of an appropriate antibiotic. Antibiotic drops of neutral pH are unlikely to sting or cause significant discomfort and, therefore, are preferred in children with an open middle ear.

Viscosity is an important attribute of ototopical medications. Drops of high viscosity tend to have long dwelling times but may not readily pass through small-diameter lumens such as tympanostomy tubes or small perforations. Combination products, usually suspensions, almost always have high viscosities. These products usually combine an antibiotic with a steroid. When hydrocortisone is used, the emulsion is generally fairly viscous. For example, neomycin and polymyxin B sulfates, bacitracin zinc, and hydrocortisone otic solution (Cortisporin otic) and ciprofloxacin (Cipro HC) have a viscosity of 4-8 centipoises. Tobramycin and dexamethasone (TobraDex), a microemulsion, has a lower viscosity of 2-4centipoises. Solutions such as ciprofloxacin HCL ophthalmic solution (Ciloxan) or ofloxacin (Floxin) have a viscosity of approximately 1 centipoise, roughly that of water.

Combination products, as mentioned previously, tend to be more viscous because the steroid component does not go readily into solution. The steroid component has a potential advantage in treating the inflammation in external otitis or in reducing granulation tissue.

Previous
Next

Conclusions

Ototopical preparations are both more effective and safer than systemic preparations when used appropriately. Not all ototopical preparations are the same. Two ototopical formulations containing the same antibiotic may differ in pH, viscosity, and the presence of steroids. Thus, 2 preparations containing the same antimicrobial agent can be different in every other respect. Consequently, substitution of one preparation for the other is unreasonable. Substituting a solution of ciprofloxacin for a solution of ofloxacin rather than choosing a suspension of ciprofloxacin with a low pH and high viscosity as a substitute is more reasonable. Substituting a combination of tobramycin and dexamethasone for a drop containing ciprofloxacin and hydrocortisone may be more appropriate, even though the active agents are different. At least these drops share the features of low pH, high viscosity, and are combination products.

Characteristics of Available Ototopical Agents

Table. (Open Table in a new window)

Ototopical Agent Components Dosing/Administration Adverse Effects Advantages Disadvantages Pathogen Coverage
Cortisporin Hydrocortisone, neomycin, polymyxin B 3 drops (children) or 4 drops (adults) qid for 10 days Stinging, ototoxicity, neomycin allergy Efficacy and potency against common pathogens, steroid component Inadequate coverage of Streptococcus pneumoniae, neomycin allergy, ototoxicity risk Pseudomonas aeruginosa, Staphylococcus aureus
Ciprodex Ciprofloxacin, dexamethasone 4 drops (children and adults) bid for 7 days Pruritis, ear discomfort Efficacy and potency against common pathogens, steroid component, convenient administration Headache (rare) Proteus mirabilis, P aeruginosa, S aureus
Floxin Otic Ofloxacin 5 drops (children) or 10 drops (adults) bid for 10 days Pruritus, reaction at application site Efficacy and potency against common pathogens, no ototoxicity, bid dosing No steroid, inconvenient administration P aeruginosa, S aureus
VoSol HC Acetic acid, hydrocortisone 3-5 drops qid (after 24-h wick placement) Stinging, burning Efficacy for some bacteria and fungi Stinging, burning due to acidic pH Some bacteria and fungi
Domeboro solution Aluminum acetate, acetic acid 4-6 drops every 2-3 hours until burning stops, then every 4-6 hours Stinging, burning Efficacy for some bacteria and fungi Stinging, burning due to acidic pH Some bacteria and fungi

For excellent patient education resources, see eMedicineHealth's patient education article Antibiotics.

Previous
 
Contributor Information and Disclosures
Author

Kathleen R Billings, MD Assistant Professor, Division of Otolaryngology-Head and Neck Surgery, Ann and Robert H Lurie Children's Hospital of Chicago

Kathleen R Billings, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Surgeons, Alpha Omega Alpha, American Society of Pediatric Otolaryngology, American Academy of Otolaryngology-Head and Neck Surgery, American Medical Association, Illinois State Medical Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Peter S Roland, MD Professor, Department of Neurological Surgery, Professor and Chairman, Department of Otolaryngology-Head and Neck Surgery, Director, Clinical Center for Auditory, Vestibular, and Facial Nerve Disorders, Chief of Pediatric Otology, University of Texas Southwestern Medical Center; Chief of Pediatric Otology, Children’s Medical Center of Dallas; President of Medical Staff, Parkland Memorial Hospital; Adjunct Professor of Communicative Disorders, School of Behavioral and Brain Sciences, Chief of Medical Service, Callier Center for Communicative Disorders, University of Texas School of Human Development

Peter S Roland, MD is a member of the following medical societies: Alpha Omega Alpha, American Auditory Society, The Triological Society, North American Skull Base Society, Society of University Otolaryngologists-Head and Neck Surgeons, American Neurotology Society, American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American Otological Society

Disclosure: Received honoraria from Alcon Labs for consulting; Received honoraria from Advanced Bionics for board membership; Received honoraria from Cochlear Corp for board membership; Received travel grants from Med El Corp for consulting.

Chief Editor

Arlen D Meyers, MD, MBA Professor of Otolaryngology, Dentistry, and Engineering, University of Colorado School of Medicine

Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cerescan;RxRevu;SymbiaAllergySolutions<br/>Received income in an amount equal to or greater than $250 from: Symbia<br/>Received from Allergy Solutions, Inc for board membership; Received honoraria from RxRevu for chief medical editor; Received salary from Medvoy for founder and president; Received consulting fee from Corvectra for senior medical advisor; Received ownership interest from Cerescan for consulting; Received consulting fee from Essiahealth for advisor; Received consulting fee from Carespan for advisor; Received consulting fee from Covidien for consulting.

Additional Contributors

Robert A Battista, MD, FACS Assistant Professor of Otolaryngology, Northwestern University, The Feinberg School of Medicine; Physician, Ear Institute of Chicago, LLC

Robert A Battista, MD, FACS is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, Illinois State Medical Society, American Neurotology Society, American College of Surgeons

Disclosure: Nothing to disclose.

References
  1. Marais J, Rutka JA. Ototoxicity and topical eardrops. Clin Otolaryngol Allied Sci. 1998 Aug. 23(4):360-7. [Medline].

  2. Dohar JE, Kenna MA, Wadowsky RM. In vitro susceptibility of aural isolates of Pseudomonas aeruginosa to commonly used ototopical antibiotics. Am J Otol. 1996 Mar. 17(2):207-9. [Medline].

  3. Samarei R. Comparison of local and systemic ciprofloxacin ototoxicity in the treatment of chronic media otitis. Glob J Health Sci. 2014 Sep 18. 6(7 Spec No):38260. [Medline].

  4. Brooks M. FDA Clears Finafloxacin Ear Drops (Xtoro) for Swimmer's Ear. Medscape Medical News. Available at http://www.medscape.com/viewarticle/836771. Accessed: December 30, 2014.

  5. Barlow DW, Duckert LG, Kreig CS, Gates GA. Ototoxicity of topical otomicrobial agents. Acta Otolaryngol. 1995 Mar. 115(2):231-5. [Medline].

  6. Brownlee RE, Hulka GF, Prazma J, Pillsbury HC 3rd. Ciprofloxacin. Use as a topical otic preparation. Arch Otolaryngol Head Neck Surg. 1992 Apr. 118(4):392-6. [Medline].

  7. Haynes DS, Rutka J, Hawke M, Roland PS. Ototoxicity of ototopical drops--an update. Otolaryngol Clin North Am. 2007 Jun. 40(3):669-83, xi. [Medline].

  8. Lawrence TL, Ayers LW, Saunders WH. Drug therapy in otomycosis: an in vitro study. Laryngoscope. 1978 Nov. 88(11):1755-60. [Medline].

  9. Linder TE, Zwicky S, Brändle P. Ototoxicity of ear drops: a clinical perspective. Am J Otol. 1995 Sep. 16(5):653-7. [Medline].

  10. Longridge NS. Topical gentamicin vestibular toxicity. J Otolaryngol. 1994 Dec. 23(6):444-6. [Medline].

  11. Lundy LB, Graham MD. Ototoxicity and ototopical medications: a survey of otolaryngologists. Am J Otol. 1993 Mar. 14(2):141-6. [Medline].

  12. Neu HC. Microbiologic aspects of fluoroquinolones. Am J Ophthalmol. 1991 Oct. 112(4 Suppl):15S-24S. [Medline].

  13. Rasmussen PA. Otitis externa and allergic contact dermatitis. Acta Otolaryngol. 1974 May. 77(5):344-7. [Medline].

  14. Rohn GN, Meyerhoff WL, Wright CG. Ototoxicity of topical agents. Otolaryngol Clin North Am. 1993 Oct. 26(5):747-58. [Medline].

  15. Roland PS, Dohar JE, Lanier BJ, et al. Topical ciprofloxacin/dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of granulation tissue in children with acute otitis media with otorrhea through tympanostomy tubes. Otolaryngol Head Neck Surg. 2004 Jun. 130(6):736-41. [Medline].

  16. Roland PS, Marple BF. Disorders of the external auditory canal. J Am Acad Audiol. 1997 Dec. 8(6):367-78. [Medline].

  17. Smith IM, Keay DG, Buxton PK. Contact hypersensitivity in patients with chronic otitis externa. Clin Otolaryngol Allied Sci. 1990 Apr. 15(2):155-8. [Medline].

  18. Tom LW. Ototoxicity of common topical antimycotic preparations. Laryngoscope. 2000 Apr. 110(4):509-16. [Medline].

  19. Tong MC, Woo JK, van Hasselt CA. A double-blind comparative study of ofloxacin otic drops versus neomycin-polymyxin B-hydrocortisone otic drops in the medical treatment of chronic suppurative otitis media. J Laryngol Otol. 1996 Apr. 110(4):309-14. [Medline].

  20. Vassalli L, Harris DM, Gradini R, Applebaum EL. Propylene glycol-induced cholesteatoma in chinchilla middle ears. Am J Otolaryngol. 1988 Jul-Aug. 9(4):180-8. [Medline].

  21. Welling DB, Forrest LA, Goll F 3rd. Safety of ototopical antibiotics. Laryngoscope. 1995 May. 105(5 Pt 1):472-4. [Medline].

  22. Wright CG, Meyerhoff WL. Ototoxicity of otic drops applied to the middle ear in the chinchilla. Am J Otolaryngol. 1984 May-Jun. 5(3):166-76. [Medline].

  23. Wright CG, Meyerhoff WL, Halama AR. Ototoxicity of neomycin and polymyxin B following middle ear application in the chinchilla and baboon. Am J Otol. 1987 Nov. 8(6):495-9. [Medline].

 
Previous
Next
 
Healthy tympanic membrane.
Tympanic membrane of a person with 12 hours of ear pain, slight tympanic membrane bulge, and slight meniscus of purulent effusion at bottom of tympanic membrane. Reproduced with permission from Isaacson G: The natural history of a treated episode of acute otitis media. Pediatrics. 1996; 98(5): 968-7.
Anatomy of the ear. 1 - skull, 2 - ear canal, 3 - pinna, 4 - tympanum, 5 - fenestra ovalis, 6 - malleus, 7 - incus, 8 - stapes, 9 - labyrinth, 10 - cochlea, 11 - auditory nerve, 12 - eustachian tube. Image courtesy of Wikimedia Commons.
Table.
Ototopical Agent Components Dosing/Administration Adverse Effects Advantages Disadvantages Pathogen Coverage
Cortisporin Hydrocortisone, neomycin, polymyxin B 3 drops (children) or 4 drops (adults) qid for 10 days Stinging, ototoxicity, neomycin allergy Efficacy and potency against common pathogens, steroid component Inadequate coverage of Streptococcus pneumoniae, neomycin allergy, ototoxicity risk Pseudomonas aeruginosa, Staphylococcus aureus
Ciprodex Ciprofloxacin, dexamethasone 4 drops (children and adults) bid for 7 days Pruritis, ear discomfort Efficacy and potency against common pathogens, steroid component, convenient administration Headache (rare) Proteus mirabilis, P aeruginosa, S aureus
Floxin Otic Ofloxacin 5 drops (children) or 10 drops (adults) bid for 10 days Pruritus, reaction at application site Efficacy and potency against common pathogens, no ototoxicity, bid dosing No steroid, inconvenient administration P aeruginosa, S aureus
VoSol HC Acetic acid, hydrocortisone 3-5 drops qid (after 24-h wick placement) Stinging, burning Efficacy for some bacteria and fungi Stinging, burning due to acidic pH Some bacteria and fungi
Domeboro solution Aluminum acetate, acetic acid 4-6 drops every 2-3 hours until burning stops, then every 4-6 hours Stinging, burning Efficacy for some bacteria and fungi Stinging, burning due to acidic pH Some bacteria and fungi
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.